(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets's offering.
Fully revised and updated, the report provides details of 811 central nervous system deals from 2020 to 2025. Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the world's leading biopharma companies.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapters 1, 2, and 3 provide introductions, trend analyses, and financial deal terms respectively. Chapter 4 reviews the top 25 most active biopharma companies, while Chapter 5 offers a detailed review of deals with available contract documents. Chapter 6 includes a directory of deals organized by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2020. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse central nervous system collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in central nervous system dealmaking
2.1. Introduction
2.2. Central nervous system partnering over the years
2.3. Central nervous system partnering by deal type
2.4. Central nervous system partnering by industry sector
2.5. Central nervous system partnering by stage of development
2.6. Central nervous system partnering by technology type
2.7. Central nervous system partnering by therapeutic indication
Chapter 3 - Financial deal terms for central nervous system partnering
3.1. Introduction
3.2. Disclosed financials terms for central nervous system partnering
3.3. Central nervous system partnering headline values
3.4. Central nervous system deal upfront payments
3.5. Central nervous system deal milestone payments
3.6. Central nervous system royalty rates
Chapter 4 - Leading central nervous system deals and dealmakers
4.1. Introduction
4.2. Most active in central nervous system partnering
4.3. List of most active dealmakers in central nervous system
4.4. Top central nervous system deals by value
Chapter 5 - Central nervous system contract document directory
5.1. Introduction
5.2. Central nervous system partnering deals where contract document available
Chapter 6 - Central nervous system dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by central nervous system therapeutic target
Deal Directory
Deal Directory - Central nervous system deals by company A-Z 2020 to 2025
Deal Directory - Central nervous system deals by technology type 2020 to 2025
Deal type definitions
Companies Featured

• 3E Bioventures Capital
• 3SBio
• 4B Technologies
• 4D Molecular Therapeutics
• 4D Pharma
• 4E Therapeutics
• 23andMe
• A*STAR' Institute of Molecular and Cell Biology
• Aachen University
• Aardvark Therapeutics
• Aarhus University Hospital
• Abbott Laboratories
• Abbvie
• AbFero Pharmaceuticals
• Abilita Therapeutics
• ABL Bio
• Abliva
• Abuse Deterrent Pharmaceuticals
• ACADIA Pharmaceuticals
• Acasti Pharma
• Accelero Biostructures
• ACEA Therapeutics
• Acelrx Pharmaceuticals
• AC Immune
• Aclarion
• Aclipse Therapeutics
• ACROBiosystems
• Actimed Therapeutics
• Acturum Life
• Aculys Pharma
• Acura Pharmaceuticals
• AcuraStem
• Adalvo
• Adamas Pharmaceuticals
• Addex Therapeutics
• Adept Neuro
• Adhera Therapeutics
• Adimune
• Adolore Biotherapeutics
• Advanced Biological Laboratories
• Adventus Ventures
• ADx NeuroSciences
• Aeromics
• AffaMed Therapeutics
• Affilogic
• Affinia Therapeutics
• AFT Pharmaceuticals
• AgeX Therapeutics
• Aguettant
• Aichi Medical University

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368168